These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35122575)

  • 41. Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence.
    Moran A; Mashele N; Mvududu R; Gorbach P; Bekker LG; Coates TJ; Myer L; Joseph Davey D
    AIDS Behav; 2022 Jan; 26(1):205-217. PubMed ID: 34287756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence on oral pre-exposure prophylaxis (PrEP) among female sex workers in eThekwini, South Africa, 2016-2020.
    Rao A; Mhlophe H; Comins C; Young K; Mcingana M; Lesko C; Mulumba N; Baral S; Hausler H; Schwartz S
    PLoS One; 2022; 17(3):e0265434. PubMed ID: 35290421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda.
    Koss CA; Havlir DV; Ayieko J; Kwarisiima D; Kabami J; Chamie G; Atukunda M; Mwinike Y; Mwangwa F; Owaraganise A; Peng J; Olilo W; Snyman K; Awuonda B; Clark TD; Black D; Nugent J; Brown LB; Marquez C; Okochi H; Zhang K; Camlin CS; Jain V; Gandhi M; Cohen CR; Bukusi EA; Charlebois ED; Petersen ML; Kamya MR; Balzer LB
    PLoS Med; 2021 Feb; 18(2):e1003492. PubMed ID: 33561143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa.
    Little KM; Hanif H; Anderson SM; Clark MR; Gustafson K; Doncel GF
    AIDS Behav; 2024 Mar; 28(3):936-950. PubMed ID: 37971614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya.
    Ortblad KF; Kearney JE; Mugwanya K; Irungu EM; Haberer JE; Barnabas RV; Donnell D; Mugo NR; Baeten JM; Ngure K
    Trials; 2019 Jul; 20(1):396. PubMed ID: 31272495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low prevalence of hepatitis B virus infection in HIV-uninfected pregnant women in Cape Town, South Africa: implications for oral pre-exposure prophylaxis roll out.
    Joseph Davey D; Hsiao NY; Wendy Spearman C; Sonderup M; Hu NC; Mashele N; Mvududu R; Myer L
    BMC Infect Dis; 2022 Sep; 22(1):719. PubMed ID: 36050648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of PrEP continuation and coverage in the first year of use: a latent class analysis of a programmatic PrEP trial in Kenya.
    Mugwanya KK; Palayew A; Schaafsma T; Irungu EM; Bukusi E; Mugo N; Morton J; Odoyo J; Ngure K; Baeten JM;
    J Int AIDS Soc; 2023 Jul; 26(7):e26137. PubMed ID: 37403405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. "I Just Decided to Stop:" Understanding PrEP Discontinuation Among Individuals Initiating PrEP in HIV Care Centers in Kenya.
    Ongolly FK; Dolla A; Ngure K; Irungu EM; Odoyo J; Wamoni E; Peebles K; Mugwanya K; Mugo NR; Bukusi EA; Morton J; Baeten JM; O'Malley G
    J Acquir Immune Defic Syndr; 2021 May; 87(1):e150-e158. PubMed ID: 33492024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
    J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Effect of PrEP Use Disclosure on Adherence in a Cohort of Adolescent Girls and Young Women in South Africa.
    Giovenco D; Pettifor A; Powers KA; Hightow-Weidman L; Pence BW; Edwards JK; Gill K; Morton JF; van der Straten A; Celum C; Bekker LG
    AIDS Behav; 2022 Apr; 26(4):1007-1016. PubMed ID: 34478015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Awareness of Heightened Sexual and Behavioral Vulnerability as a Trigger for PrEP Resumption Among Adolescent Girls and Young Women in East and Southern Africa.
    Reddy K; Palanee-Phillips T; Heffron R
    Curr HIV/AIDS Rep; 2023 Dec; 20(6):333-344. PubMed ID: 38051383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-exposure prophylaxis for South African adolescents: What evidence?
    Bekker LG; Gill K; Wallace M
    S Afr Med J; 2015 Nov; 105(11):907-11. PubMed ID: 26632316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa.
    Rao A; Lesko C; Mhlophe H; Rucinski K; Mcingana M; Pretorius A; Mcloughlin J; Baral S; Beyrer C; Hausler H; Schwartz S
    AIDS; 2023 May; 37(6):977-986. PubMed ID: 36723509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding Demand for PrEP and Early Experiences of PrEP Use Among Young Adults in Rural Kenya and Uganda: A Qualitative Study.
    Camlin CS; Koss CA; Getahun M; Owino L; Itiakorit H; Akatukwasa C; Maeri I; Bakanoma R; Onyango A; Atwine F; Ayieko J; Kabami J; Mwangwa F; Atukunda M; Owaraganise A; Kwarisiima D; Sang N; Bukusi EA; Kamya MR; Petersen ML; Cohen CR; Charlebois ED; Havlir DV
    AIDS Behav; 2020 Jul; 24(7):2149-2162. PubMed ID: 31955361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.
    Vazquez L; Moll AP; Kacin A; Ndlovu NE; Shenoi SV
    AIDS Patient Care STDS; 2019 May; 33(5):214-219. PubMed ID: 31067125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
    BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.